Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
5 Market-Beating Stocks Backed by Women Power
by Sweta Killa
Occidental Petroleum (OXY), Northrop (NOC), Hershey (HSY), Commercial Metals (CMC) and Vertex Pharma (VRTX) are among the stocks that are outperforming the market this year and are headed by female CEOs.
Merck (MRK) Outperforms Industry, What's in Store for 2022?
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.
Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y
by Zacks Equity Research
Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.
Intercept (ICPT) Q4 Earnings & Sales Beat, Ocaliva in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the fourth quarter and sales beat estimates.
Kodiak (KOD) Down More Than 80% in Past 3 Months: Here's Why
by Zacks Equity Research
Kodiak Sciences (KOD) is developing its lead candidate, KSI-301, for treating various retinal vascular diseases. The recent setback for KSI-301 has hurt the stock.
ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the United States.
Horizon (HZNP) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Horizon's (HZNP) revenues beat estimates in the fourth quarter of 2021. Shares rise following the results.
Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
FATE's Loss Wider Than Expected in Q4, Pipeline in Focus
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the fourth quarter.
Endo (ENDP) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.
Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked
by Zacks Equity Research
Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.
VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment
by Zacks Equity Research
VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.
Why Is Vertex (VRTX) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.
Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.
Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.
Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.
Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Moderna (MRNA) Q4 Earnings Top, COVID-19 Vaccine Brings $7B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter. Stock gains in pre-market.
BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines
Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.
AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.